Pacific Biosciences of California PACB Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's operating lease right-of-use asset amortization?
- Pacific Biosciences of California (PACB) reported operating lease right-of-use asset amortization of $849K in Q1 2026.
- How has Pacific Biosciences of California's operating lease right-of-use asset amortization changed year-over-year?
- Pacific Biosciences of California's operating lease right-of-use asset amortization decreased by 32.5% year-over-year, from $1.26M to $849K.
- What is the long-term trend for Pacific Biosciences of California's operating lease right-of-use asset amortization?
- Over 3 years (2022 to 2025), Pacific Biosciences of California's operating lease right-of-use asset amortization has grown at a -16.9% compound annual growth rate (CAGR), from $6.93M to $3.98M.